Disease Markers

Research Article

Effects of Long-Term Statin Therapy in Coronary Artery Disease Patients with or without Chronic Kidney Disease

Table 4

Unadjusted predictors for MACE.
 Hazard ratio95% CI value
CKD versus CAD + CKD0.43(0.34, 0.55)<0.001
CKD versus CAD 0.14(0.07, 0.28)<0.001
Age (years)1.03(1.01, 1.04)<0.001
Male (versus female)0.78(0.61, 0.99)0.045
Hypertension1.42(1.11, 1.82)<0.01
Diabetes mellitus1.21(0.94, 1.54)0.134
Smoking1.42(1.13, 1.79)<0.01
Myocardial infarction1.25(1.0, 1.57)0.055
Angina pectoris1.13(0.90, 1.42)0.28
Stroke1.44(0.91, 2.27)0.118
Ejection fraction0.99(0.98, 1.00)0.165
Calcium-channel blocker1.13(0.88, 1.44)0.346
ACEI1(0.80, 1.26)0.983
ARB0.94(0.75, 1.19)0.627
β-blocker1.49(1.14, 1.94)<0.01
Loop diuretic1.15(0.79, 1.66)0.475
Aspirin2.21(1.40, 3.48)<0.01
Clinical parameters at baseline   
Total cholesterol (mmol/l)0.96(0.87, 1.05)0.319
LDL-C (mmol/l)1.002(1.001, 1.003)<0.001
HDL-C (mmol/l)0.78(0.52, 1.19)0.251
Triglycerides (mmol/l)0.98(0.88, 1.08)0.65
HbA1c (%)0.98(0.88, 1.09)0.728
Glucose (mmol/l)1(0.99, 1.01)0.614
SBP (mmHg)0.994(0.99, 1.0)0.011
DBP (mmHg) 0.99(0.98, 1.0)0.011
Clinical parameters at final observation   
Total cholesterol (mmol/l)1.31(1.19, 1.44)<0.001
LDL-C (mmol/l)1.26(1.13, 1.41)<0.001
HDL-C (mmol/l)1.04(0.68, 1.60)0.846
Triglycerides (mmol/l)1.09(0.97, 1.21)0.135
HbA1c (%)1.02(0.92, 1.14)0.702
Glucose (mmol/l)1.1(1.06, 1.15)<0.001
SBP (mmHg)1.006(1.0, 1.01)0.046
DBP (mmHg)0.997(0.99, 1.01)0.545
Statins 0.247(0.19, 0.38)<0.001
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; CAD, coronary artery disease; CKD, chronic kidney disease; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiovascular event; SBP, systolic blood pressure.